Skip to main content
Eli Lilly and Company logo

Eli Lilly and Company

4.0
LLY

A Eli Lilly and Company Company

www.lilly.com
Location
Indianapolis, Indiana
Size
10,001+ employees
Revenue
$10+ billion (USD)
Industry
Pharmaceutical Manufacturing
Founded
1876

Eli Lilly and Company: Nearly 150 Years of Transforming Science Into Healing

Eli Lilly and Company stands as a global pharmaceutical leader dedicated to turning science into life-changing medicines. Founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana, this Fortune 500 organization has grown to employ over 10,000 professionals worldwide with annual revenues exceeding $10 billion. With a strong presence across major U.S. cities and international locations, Lilly continues its founder's vision: "Take what you find here and make it better and better."

Scientific Innovation Across Critical Health Areas

Harnessing the power of biotechnology, chemistry, and genetic medicine, Lilly's scientists urgently advance breakthrough discoveries in:

  • Diabetes care and metabolic disease
  • Oncology and cancer therapeutics
  • Immunology and inflammatory conditions
  • Neuroscience and neurological disorders

The company's commitment to scientific excellence drives innovation across research and development, clinical trials, regulatory affairs, manufacturing, and commercial operations.

Career Excellence and Professional Growth

  • 1,000+ active opportunities spanning research, clinical development, manufacturing, and corporate functions
  • Comprehensive training programs and professional development initiatives at all career levels
  • Competitive compensation with robust health benefits and retirement planning
  • Global career mobility across international operations and diverse therapeutic areas
  • Meaningful impact contributing to breakthrough medical discoveries that improve lives worldwide

Values Driven Culture

Lilly's corporate culture is built on three foundational values: excellence, integrity, and respect for people. These principles guide every aspect of the organization, creating an environment where employees thrive while advancing medical science. With a 4.0 Glassdoor rating, the company demonstrates its commitment to both scientific advancement and employee satisfaction.

Community Impact and Purpose

Beyond pharmaceutical innovation, Lilly's dedication to making life better extends to substantial community philanthropy and volunteer initiatives. Employees have opportunities to contribute meaningfully both professionally and personally, giving back to communities through service and support.

Mission

We're a medicine company turning science into healing to make life better for people around the world.

Frequently Asked Questions

Lilly to acquire Orna Therapeutics to advance cell therapies

Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive...

Read Full Article

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound. Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges. Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2...

Read Full Article

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility

The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide Company plans to create more than 2,800 manufacturing and construction jobs at Lilly's 10th U.S. manufacturing site announced since 2020 INDIANAPOLIS, Jan. 30, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania. The site will serve as Lilly's newest...

Read Full Article

Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

INDIANAPOLIS, Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's...

Read Full Article

Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a novel folate receptor alpha (FRα)...

Read Full Article